AML with BCR-ABL1 Fusion treated with Imatinib, a Hypomethylating Agent and Venetoclax

AML with BCR-ABL1 Fusion treated with Imatinib, a Hypomethylating Agent and Venetoclax

A patient with history of myelodysplastic syndrome (MDS) presented with multifocal pneumonia and was found to have Philadelphia chromosomepositive (Ph+) acute myeloid leukemia (AML). A tyrosine kinase inhibitor (TKI) was added to decitabine and venetoclax combination, providing a molecular and cytog...

Full description

Bibliographic Details
Main Authors: Soon Khai Low, Suparna Nanua, Mehul Patel, Anne S Renteria
Format: Article
Language:English
Published: Elsevier 2022-01-01
Series:Leukemia Research Reports
Subjects:
Acute myeloid leukemia
Philadelphia chromosoome
Decitabine
Venetoclax
Tyrosine kinase inhibitor
Online Access:http://www.sciencedirect.com/science/article/pii/S2213048922000450

Internet

http://www.sciencedirect.com/science/article/pii/S2213048922000450

Similar Items